© 2005 Oxford University Press
ARTICLE |
p53-Defective Tumors With a Functional Apoptosome-Mediated Pathway: A New Therapeutic Target
Affiliations of authors: Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan (T. Mashima, TO, SS, MM, YS, KY, TY, TT); Division of Cancer-Related Genes, Institute for Genetic Medicine, Hokkaido University School of Medicine, Sapporo, Japan (T. Moriuchi, JH, MT); Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan (YI, YK); Kitasato Institute for Life Sciences & Graduate School of Infection Control Sciences, Kitasato University, Tokyo, Japan (HT); Department of Chemotherapy, Kyoritsu University of Pharmacy, Tokyo, Japan (YS); Institute of Molecular and Cellular Biosciences, the University of Tokyo, Tokyo, Japan (TT)
Correspondence to: Takashi Tsuruo, PhD, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, 3–10–6 Ariake, Koutou-ku, Tokyo, Japan 135–8550 (e-mail: ttsuruo{at}iam.u-tokyo.ac.jp).
Background: Although cancer cells appear to maintain the machinery for intrinsic apoptosis, defects in the pathway develop during malignant transformation, preventing apoptosis from occurring. How to specifically induce apoptosis in cancer cells remains unclear. Methods: We determined the apoptosome activity and p53 status of normal human cells and of lung, colon, stomach, brain, and breast cancer cells by measuring cytochrome c–dependent caspase activation and by DNA sequencing, respectively, and we used COMPARE analysis to identify apoptosome-specific agonists. We compared cell death, cytochrome c release, and caspase activation in NCI-H23 (lung cancer), HCT-15 (colon cancer), and SF268 (brain cancer) cells treated with Triacsin c, an inhibitor of acyl-CoA synthetase (ACS), or with vehicle. The cells were mock, transiently, or stably transfected with genes for Triacsin c–resistant ACSL5, dominant negative caspase-9, or apoptotic protease activating factor-1 knockdown. We measured ACS activity and levels of cardiolipin, a mitochondrial phospholipid, in mock and ACSL5-transduced SF268 cells. Nude mice carrying NCI-H23 xenograft tumors (n = 10) were treated with Triacsin c or vehicle, and xenograft tumor growth was assessed. Groups were compared using two-sided Student t tests. Results: Of 21 p53-defective tumor cell lines analyzed, 17 had higher apoptosome activity than did normal cells. Triacsin c selectively induced apoptosome-mediated death in tumor cells (caspase activity of Triacsin c–treated versus untreated SF268 cells; means = 1020% and 100%, respectively; difference = 920%, 95% CI = 900% to 940%; P<.001). Expression of ACSL5 suppressed Triacsin c–induced cytochrome c release and subsequent cell death (cell survival of Triacsin c–treated mock- versus ACSL5-transduced SF268 cells; means = 40% and 83%, respectively; difference = 43%, 95% CI = 39% to 47%; P<.001). ACS was also essential to the maintenance of cardiolipin levels. Finally, Triacsin c suppressed growth of xenograft tumors (relative tumor volume on day 21 of Triacsin c–treated versus untreated mice; means = 4.6 and 9.6, respectively; difference = 5.0, 95% CI = 2.1 to 7.9; P = .006). Conclusions: Many p53-defective tumors retain activity of the apoptosome, which is therefore a potential target for cancer chemotherapy. Inhibition of ACS may be a novel strategy to induce the death of p53-defective tumor cells.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  E. C. Ledgerwood and I. M. Morison Targeting the Apoptosome for Cancer Therapy Clin. Cancer Res., January 15, 2009; 15(2): 420 - 424. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. P. C. Wong, W. P. Tsang, P. Y. Chau, N. N. Co, T. Y. Tsang, and T. T. Kwok p53-R273H gains new function in induction of drug resistance through down-regulation of procaspase-3 Mol. Cancer Ther., March 1, 2007; 6(3): 1054 - 1061. [Abstract] [Full Text] [PDF]
|
|